ICL Group Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICL research report →
Range $5.75 – $6.5
Price Chart
About the company
ICL Group Ltd, a global enterprise specializing in the production of minerals and chemicals, conducts its operations through four distinct business units. The company, which originated as Israel Chemicals Ltd and adopted its current name in May 2020, was founded in 1968 and maintains its headquarters in Tel Aviv, Israel. The Industrial Products segment is responsible for extracting bromine from a byproduct solution generated during potash production, subsequently manufacturing bromine-based compounds.
- CEO
- Elad Aharonson
- IPO
- 2005
- Employees
- 13,007
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on ICL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.58B
- P/E
- 20.97
- Fwd P/E
- 12.21
- PEG
- -1.47
- P/S
- 0.85
- P/B
- 1.06
- EV/EBITDA
- 6.40
- Div Yield
- 0.03%
- Gross Margin
- 30.63%
- Op Margin
- 10.87%
- Net Margin
- 3.96%
- ROE
- 5.02%
- ROIC
- 5.04%
Latest fiscal year · YoY change
- Revenue
- $7.15B+4.6%
- Gross Profit
- $2.19B-3.1%
- Op Income
- $703.00M
- Net Income
- $226.00M-44.5%
- EPS
- $0.18-43.8%
- OCF Growth
- -30.0%
- FCF Growth
- -80.0%
- 52W High
- $6.97
- 52W Low
- $4.76
- 50D MA
- $5.42
- 200D MA
- $5.44
- Beta
- 1.05
- RSI (14)
- 40
- Avg Volume
- 1.18M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ICL reported a strong second quarter with sales and EBITDA up sharply year over year, while laying out a new segment structure and a cost-saving program aimed at boosting margins and cash generation.· August 5, 2026
- Q2 sales were $2.1 billion, up 17% year over year, and adjusted EBITDA was $448 million, up 28%.
- Adjusted EPS was $0.12, adjusted net income was $149 million, operating cash flow was $290 million, and free cash flow was $94 million.
- Industrial Products, Potash, and Phosphate Solutions all grew; Growing Solutions had higher sales but lower EBITDA because of higher input costs.
- Management reiterated 2026 consolidated EBITDA guidance of $1.5 billion to $1.7 billion and potash volume guidance of 4.5 million to 4.7 million metric tons.
- ICL announced a new 4-segment structure effective in Q1 2027 and a cost program, Elevate, targeting more than $150 million of annual EBITDA improvement by end-2027 and more than $350 million by end-2028.
ICL reported second-quarter sales of $2.1 billion, up 17% year over year, and adjusted EBITDA of $448 million, up 28%. Adjusted net income was $149 million, adjusted EPS was $0.12, operating cash flow was $290 million, and free cash flow was $94 million. Industrial Products sales were $414 million with EBITDA of $130 million; Potash sales were $468 million with EBITDA of $154 million; Phosphate Solutions sales were $722 million with EBITDA of $136 million; and Growing Solutions sales were $605 million with EBITDA of $50 million. Management said the quarter absorbed $100 million of higher raw material costs and more than $40 million of exchange rate impact. For 2026, ICL reiterated consolidated EBITDA guidance of $1.5 billion to $1.7 billion, potash sales volumes of 4.5 million to 4.7 million metric tons, and an annual adjusted tax rate of approximately 30%.
Elad Aharonson framed the quarter as evidence that ICL’s core businesses are performing well while the company reshapes its portfolio around growth markets. He highlighted the new organizational structure, with dedicated Nutrition Solutions and Industrial Products segments, as a way to better align reporting with end markets and improve visibility for investors. He also emphasized Elevate as a company-wide push to reduce cost, improve cash generation, and support margin expansion, saying the company is committed to reaching the $350 million annual EBITDA-improvement target by the end of 2028.
Asaf Alperovitz pointed to a strong balance sheet and cash profile, citing $2.2 billion of available cash resources, net debt to adjusted EBITDA of 1.5x, and the successful completion of an $800 million senior notes offering. He noted that ICL distributed 50% of adjusted net income to shareholders, equal to a $75 million dividend in the second quarter and a trailing 12-month dividend yield of 4.1%. On outlook, he reiterated 2026 consolidated EBITDA guidance of $1.5 billion to $1.7 billion, explained that higher sulfur costs and currency headwinds weigh on the range, and said potash volumes are still expected to be 4.5 million to 4.7 million metric tons.
Analysts focused on Industrial Products margin sustainability, the pace and confidence behind Elevate, sulfur supply and pricing, potash market stability, Brazil softness, and the potential impact of sodium-ion batteries on LFP demand. Management said Q2 Industrial Products benefited from high bromine prices, with bromine around $4,500 per ton currently after peaking above $6,000 in April, and said they can still lock in transactions. On sulfur, management said it is a major second-half challenge because of both availability and price, but that they have secured quantities for Q3 and early Q4 and do not plan to cut production. For Brazil, they said the market is weak and Growing Solutions should have a weaker Q3 than normal, while for LFP they said demand is still increasing and they do not see concern over the next 5 years.
The call showed broad year-over-year growth across all four businesses, with especially strong performance in Industrial Products and Potash. Management also sounded confident that Elevate and the new structure can unlock meaningful efficiency gains, and they said bromine and potash pricing remained supportive. The company ended the quarter with strong liquidity and reaffirmed full-year EBITDA guidance.
Management repeatedly flagged sulfur as a significant second-half headwind, citing higher costs, supply tightness, and likely phosphate margin pressure as higher-priced inventory is consumed. Brazil was described as weak, especially for specialty fertilizers, which could limit Growing Solutions performance in the seasonally important third quarter. Currency pressure from the shekel and the possibility that second-half results come in below the first half were also highlighted.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 56.0%
- Shares Outstanding
- 1.29B
- Float Shares
- 723.37M
of shares held by institutions
221 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ICL, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 29.07M | ▲ 382.78K |
| Altshuler Shaham Ltd | 23.97M | ▲ 1.70M |
| Norges Bank | 21.30M | ▲ 21.30M |
| Vanguard Capital Management LLC | 20.92M | ▲ 240.88K |
| Clal Insurance Enterprises Holdings Ltd | 19.81M | ▼ 2.23M |
| Y.D. More Investments Ltd | 19.50M | ▼ 119.15K |
| Phoenix Holdings Ltd. | 15.58M | ▲ 264.69K |
| Morgan Stanley | 9.84M | ▲ 2.37M |
| Vanguard Fiduciary Trust Co | 6.46M | ▲ 73.24K |
| Blackrock, Inc. | 5.73M | ▲ 1.21M |
| Goldman Sachs Group Inc | 5.48M | ▲ 2.46M |
| Legal & General Group PLC | 4.49M | ▲ 141.90K |
Held by 25 ETFs
Biggest fund positions in ICL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 4, 26 | Kilstein Alegra | other | 731,707 |
| Aug 4, 26 | Alperovitz Asaf | other | 1,829,268 |
| Jun 14, 26 | Alperovitz Asaf | other | 0 |
| May 24, 26 | Kilstein Alegra | other | 0 |
| Mar 18, 26 | Perelman Uri | other | 1,139,990 |
| Mar 18, 26 | Perelman Uri | other | 739,400 |
| Mar 18, 26 | Doppelt Yoav | other | 1,055,100 |
| Mar 18, 26 | Doppelt Yoav | other | 1,973,684 |
| Mar 18, 26 | Kabalek Yaniv | other | 348,928 |
| Mar 18, 26 | Kabalek Yaniv | other | 627,793 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ICL coverage
Recent articles, reports, and earnings notes.
No research on ICL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ICL report →3 Fertilizer Stocks to Keep an Eye on Amid Industry Headwinds
zacks.com · Oct 1
Why ICL Group (ICL) is a Great Dividend Stock Right Now
zacks.com · Sep 21
Reviewing ICL Group (NYSE:ICL) & FUCHS (OTCMKTS:FUPBY)
defenseworld.net · Sep 18
ICL Group (ICL) Upgraded to Buy: Here's Why
zacks.com · Sep 16
Why ICL Group (ICL) is a Top Dividend Stock for Your Portfolio
zacks.com · Sep 3
Westaim (OTCMKTS:WEDXF) & ICL Group (NYSE:ICL) Critical Review
defenseworld.net · Aug 24
ICL Group Q2 Earnings Call Highlights
marketbeat.com · Aug 8
Amundi Buys 370,457 Shares of ICL Group Ltd. $ICL
defenseworld.net · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.